SY-104

N/A

Report date: 2024/05/28 16:37:11
First In Class

Base Information

Drug NameSY-104
Drug Alias NameSY-104
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapy
Mechanisms of ActionNY-ESO-1 gene transference
TargetsCancer/testis antigen 1
Therapy Area/IndicationsMultiple MyelomaSarcoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesReplay Holdings LLC
China Registration ClassN/A

Develop Information

Active CompaniesReplay Holdings LLC
Inactive CompaniesN/A
Active IndicationsMultiple MyelomaSarcoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A